Telemetry Investments' Q3 vs. Q4 13F Holdings: Winners, Losers, and Trends
Ava Hoppe | 4 May, 2023
As an investor, staying on top of changes in fund holdings can provide valuable insights into market trends and emerging opportunities. Telemetry Investments' latest 13F filings reveal interesting shifts in the firm's portfolio. In this article, we'll delve into the winners, losers, and overall trends in Telemetry's Q3 vs. Q4 2022 holdings.
First up, the winners. Among Telemetry's highest gainers were Moneygram Intl Inc (MGI), a money transfer company that saw a whopping 47.9% increase in shares. The pharmaceutical company, Amryt Pharma PLC (AMYT), also saw a healthy 11.8% increase. Bioplus Acquisition Corp (BIOS) and Valuence Merger Corp I (VMCAU) were other notable winners, with 2.7% and 2.3% increases, respectively.
On the flip side, there were a handful of losers among Telemetry's Q3 vs. Q4 holdings. Eiger BioPharmaceuticals (EIGR) saw a sharp drop of 69.7% in shares, while Mind Medicine MindMed Inc (MNMD) decreased by 42.8%. Nabors Industries Ltd (NBR) and Tegna Inc (TGNA) were also among the losers, experiencing a 12.7% and 19.9% decrease in shares, respectively.
Looking at overall trends, one of the most interesting takeaways from Telemetry's filings was the significant increase in the shares of Silver Spike Acquisiton (SPKB). The special purpose acquisition company saw a small 1.7% increase in shares, but the value of those shares increased from $2.7 million to $2.8 million. This suggests that Telemetry may be placing more emphasis on SPAC investments in the future.
Another trend we noticed was the growing interest in healthcare and pharmaceuticals among Telemetry's holdings. Atyr Pharma Inc (LIFE), Paratek Pharmaceuticals Inc (PRTK), and Esperion Therapeutics Inc NE (ESPR) all saw substantial increases in shares. This could be a response to the ongoing COVID-19 pandemic and a desire to invest in companies that are leading the charge in medical advancements.
Overall, Telemetry's Q3 vs. Q4 holdings provide a snapshot of the firm's current investment strategies and interests. While there were some notable losers, there were also several winners and emerging trends that investors should keep an eye on moving forward.
Other Posts
- An Overview of Fusion Family Wealth LLC's Q4 2022 vs. Q1 2023 13F Holdings
- Navigating New Frontiers: How Riverspan Partners' Investment in Barretts Minerals is Changing the Game in Industrial Minerals
- Valicenti Advisory Services Inc Q3 2023 vs. Q4 2023 13F Holdings Comparison
- Bel Air Investment Advisors LLC Q1 vs. Q2 2021: Comparing 13F Holdings
- Flaharty Asset Management Q3/Q4 2022 Holdings Comparison: Which Stocks Saw the Biggest Changes in Investments?
- Grey Rock Forms Partnership with CarbonCycle to Revolutionize Carbon Capture and Sequestration Platform
- MUFG Fund Makes No Changes to Holdings in Morgan Stanley in Q3-Q4 2022
- Investing in the Future: Sustainable Growth Advisers, LP Q3 2022 vs. Q4 2022 13F Holdings Comparison
- FDx Advisors, Inc. Q1 2023 vs. Q2 2023 13F Holdings Comparison
- Navigating the Financial Waters: Hennessy Advisors' Q1 2024 Portfolio Shifts Unveiled